Get to Know Dr. Jay M. Lee
Since acquiring his medical degree in 1997, Dr. Jay M. Lee has distinguished himself as one of the nation’s top thoracic surgeons for mesothelioma. After graduating from UCLA School of Medicine with honors, Lee pursued his residency at Duke University Medical Center and Georgetown University Medical Center.
He later completed fellowships at Memorial Sloan Kettering Cancer Center and Brigham and Women’s Hospital, both world-renowned centers for the treatment of mesothelioma and lung cancer. The experience he gained from working with other top doctors in thoracic surgery became invaluable to his practice.
The research that Lee supervises also extends to clinical trials. He has a passion for pioneering new lung cancer therapies and has directed several clinical trials, published studies in peer-reviewed journals and become an investigator for the UCLA Lung Cancer Research Program.
Lee’s specific research interests are immunotherapy, nanotechnology applications for lung cancer treatment and gene therapy. Lee’s lung cancer research has won several grants from the National Institutes of Health, National Cancer Institute, the Jonsson Cancer Center Foundation, the Ernst A. Noltmann memorial fund and the American Society of Gene & Cell Therapy.
His other clinical focuses include chest malignancies, esophageal cancers, general cardiothoracic surgery, pleural effusions, pleural tumors, pericardial effusions, minimally invasive surgery, thoracoscopic surgery and video-assisted thoracoscopic surgery.
Specialties of Dr. Jay M. Lee
- Pleural and lung cancer
- Pericardial mesothelioma
- Gene therapy
Dr. Jay M. Lee’s Experience and Medical Education
- UCLA School of Medicine (M.D.)
- Georgetown University Medical Center (Internship and residency)
- Duke University Medical Center (Residency)
- Brigham and Women’s Hospital (Fellowship)
- Memorial Sloan Kettering Cancer Center (Fellowship)
Awards and Certifications
- Board certified in surgery, American Board of Surgery (2004)
- Board certified in cardiothoracic surgery, American Board of Thoracic Surgery (2009)
Publications of Dr. Jay M. Lee
- Dubinett, S.M. et al. (2011, July 1). Chemokines: Can Effector Cells be Re-directed to the Site of Tumor? The Cancer Journal.
- Baratelli, F. et al. (2010, June 30). PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. American Journal of Translational Research.
- Yanagawa, J. et al. (2009, November). Snail Promotes CXCR2 Ligand-Dependent Tumor Progression in Non-Small Cell Lung Carcinoma. Clinical Cancer Research.
- Lee, J.M. et al. (2008, June). Inflammation in lung carcinogenesis: New targets for lung cancer chemoprevention and treatment. Oncology/Hematology.
- Lee, J.M., Mao, J.T., Krysan, K. & Dubinett, S.M. (2007, March 26). Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncology.
Thank you for your feedback. Would you like to speak with a Patient Advocate?